How Can We Help a Patient With a Small Failing Bioprosthesis?: An In Vitro Case Study

JACC Cardiovasc Interv. 2015 Dec 28;8(15):2026-2033. doi: 10.1016/j.jcin.2015.08.028. Epub 2015 Nov 27.

Abstract

Objectives: The aim of this study was to investigate the hemodynamic performance of a transcatheter heart valve (THV) deployed at different valve-in-valve positions in an in vitro model using a small surgical bioprosthesis.

Background: Patients at high surgical risk with failing 19-mm surgical aortic bioprostheses are not candidates for valve-in-valve transcatheter aortic valve replacement, because of risk for high transvalvular pressure gradients (TVPGs) and patient-prosthesis mismatch.

Methods: A 19-mm stented aortic bioprosthesis was mounted into the aortic chamber of a pulse duplicator, and a 23-mm low-profile balloon-expandable THV was deployed (valve-in-valve) in 4 positions: normal (bottom of the THV stent aligned with the bottom of the surgical bioprosthesis sewing ring) and 3, 6, and 8 mm above the normal position. Under controlled hemodynamic status, the effect of these THV positions on valve performance (mean TVPG, geometric orifice area, and effective orifice area), thrombotic potential (sinus shear stress), and migration risk (pullout force and embolization flow rate) were assessed.

Results: Compared with normal implantation, a progressive reduction of mean TVPG was observed with each supra-annular THV position (normal: 33.10 mm Hg; 3 mm: 24.69 mm Hg; 6 mm: 19.16 mm Hg; and 8 mm: 12.98 mm Hg; p < 0.001). Simultaneously, we observed increases in geometric orifice area (normal: 0.83 cm(2); 8 mm: 1.60 cm(2); p < 0.001) and effective orifice area (normal: 0.80 cm(2); 8 mm: 1.28 cm(2); p < 0.001) and reductions in sinus shear stresses (normal: 153 dyne/cm(2); 8 mm: 40 dyne/cm(2); p < 0.001), pullout forces (normal: 1.55 N; 8 mm: 0.68 N; p < 0.05), and embolization flow rates (normal: 32.91 l/min; 8 mm: 26.06 l/min; p < 0.01).

Conclusions: Supra-annular implantation of a THV in a small surgical bioprosthesis reduces mean TVPG but may increase the risk for leaflet thrombosis and valve migration. A 3- to 6-mm supra-annular deployment could be an optimal position in these cases.

Keywords: small bioprosthesis; transcatheter aortic valve; valve-in-valve.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aortic Valve / physiopathology
  • Aortic Valve / surgery*
  • Bioprosthesis*
  • Cardiac Catheterization / adverse effects
  • Cardiac Catheterization / instrumentation*
  • Equipment Failure Analysis
  • Heart Valve Diseases / diagnosis
  • Heart Valve Diseases / physiopathology
  • Heart Valve Diseases / surgery
  • Heart Valve Diseases / therapy*
  • Heart Valve Prosthesis Implantation / adverse effects
  • Heart Valve Prosthesis Implantation / instrumentation*
  • Heart Valve Prosthesis*
  • Hemodynamics*
  • Humans
  • Materials Testing
  • Models, Anatomic
  • Prosthesis Design
  • Prosthesis Failure*
  • Thrombosis / etiology